ALZN earnings analysis
What we found in ALZN's 10-K: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Alzamend remains a pre-revenue, clinical-stage biotechnology company with $0 revenue in FY2026 and an $8.77 million net loss, up from a $4.51 million loss in FY2025. Its central strategic value proposition is differentiated lithium brain delivery through AL001, with healthy-subject results showing bioequivalent blood exposure and faster peak brain uptake; however, execution is constrained by only $0.71 million of year-end cash, an auditor going-concern warning, and a September 16, 2026 Nasdaq equity-compliance deadline. The AL001 roadmap continues into late 2026 and 2027, while ALZN002 is materially delayed by the unresolved replacement-CRO search.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- AL001 data support differentiated brain PK
- AL001 is the lead program and targets Alzheimer’s, bipolar disorder, MDD and PTSD. In a healthy-subject study, AL001 delivered 101% of total lithium blood exposure and 97% of peak lithium levels versus lithium carbonate, reached peak brain concentration in 6.7 hours versus 8.4 hours, and showed numerically higher lithium concentrations across measured brain regions.
- Two-asset neuropsychiatric pipeline strategy
- The strategy is to develop two licensed, worldwide product candidates: AL001, a lithium/salicylate/proline ionic cocrystal, and ALZN002, an autologous cell-based Alzheimer’s immunotherapy. Management is pursuing five Phase II AL001 imaging trials across healthy subjects, Alzheimer’s, BD, MDD and PTSD.
- Clinical investment accelerated sharply
- R&D expense rose 157% to $3.63 million in FY2026, driven principally by clinical-trial fees that increased 310% to $2.93 million. The spending increase reflects progression of the AL001 clinical program rather than commercial revenue, which remained $0.
- Equity financing remains primary funding source
- The company raised $4.83 million of financing cash in FY2026: $4.04 million from convertible preferred stock and $0.80 million from its ATM program. After fiscal year-end through July 22, 2026, it raised a further $0.63 million through the ATM by selling 535,486 shares.
- Cash deployed to operations, not shareholder returns
- Capital allocation is focused on clinical development and corporate infrastructure: operating cash use was $8.07 million in FY2026, while there were no investing activities, issuer share repurchases, or cash dividends. The company states it does not expect to pay cash dividends in the foreseeable future.
- Loss expanded as cash runway deteriorated
- The FY2026 loss widened to $8.77 million from $4.51 million in FY2025, while loss per share improved to $2.63 from $11.32 because weighted-average shares increased to 3.34 million from 0.45 million. Cash declined to $0.71 million from $3.95 million.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Going-concern risk and acute funding gap
- The auditor included a going-concern emphasis paragraph. Cash was only $710,689 at April 30, 2026, versus FY2026 operating cash use of $8.07 million, and management explicitly states current cash is insufficient to fund planned operations through the next 12 months; accumulated deficit was $67.3 million.
- Nasdaq listing compliance deadline
- Nasdaq notified the company on March 20, 2026 that it failed the $2.5 million minimum stockholders’ equity requirement: equity was approximately $2.2 million at January 31, 2026 and fell to $0.73 million at April 30, 2026. Nasdaq granted an extension only through September 16, 2026 to regain compliance.
- ALZN002 CRO delay and litigation cost
- ALZN002 remains delayed after CRO Biorasi terminated its contract in February 2024. Management says it has been unable to identify a suitable replacement CRO with the required expertise and capacity and does not expect to restart the Phase I/IIA trial in Q1 2027; FY2026 legal fees rose to $1.9 million from $0.24 million, primarily related to the Biorasi lawsuit.
- Material weakness in financial controls
- Management concluded that internal control over financial reporting was ineffective at April 30, 2026 because the accounting department lacked resources to sufficiently review manual journal entries, reconciliations, financial statements and non-routine transactions. Remediation requires increasing accounting resources, and the weakness is not considered remediated.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-2.63
- Segment
- Single reportable segment; the company generated $0 revenue and has two clinical-stage candidates, AL001 and ALZN002.
What they said about what is next.
No numeric revenue or EPS outlook was provided in the 10-K. Management expects full AL001 healthy-subject PK/PD results in August 2026; BD-study topline data in Q4 2026; MDD and PTSD studies to commence in Q4 2026; and the Alzheimer’s study to commence in Q1 2027. It does not expect to restart the ALZN002 Phase I/IIA study in Q1 2027.
The filing reads worse than the one before it.
What came before.
- 10-Q · March 11, 2026
- Alzamend Neuro, Inc. reported a significant operational loss for the third quarter of fiscal 2026, with no revenue generated during the period. Adjusted EPS improved to -$0.58 compared to -$1.75 year-over-year,…
- 10-Q · December 9, 2025
- Alzamend Neuro's Q2 results for fiscal year 2025 reflect a significant improvement in earnings dynamics despite generating no revenue. The net loss decreased to $1.0 million from $1.4 million, translating to a…
- 10-Q · September 10, 2025
- Alzamend Neuro, Inc. reported a quarterly net loss of $2.7 million with zero revenue for the three months ended July 31, 2025, maintaining the trend from the previous year. Operating expenses rose significantly due to…
- 10-K · July 22, 2025
- Alzamend Neuro, Inc. reported a substantial reduction in its losses for the fiscal year ending April 30, 2025, with a net loss of $4.5 million, down from $9.9 million the previous year. The company has not yet generated…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ALZN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever